Clinical Trials
60 trialsA Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Janssen Pharmaceutical K.K.
A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms
Kyowa Kirin Co., Ltd.
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies
Daiichi Sankyo
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
BEXMAB
Faron Pharmaceuticals Ltd
Durvalumab and Tremelimumab for Pediatric Malignancies
AstraZeneca
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
ADAPT-HEM
Beijing Biotech
Study of AZD9829 in CD123+ Hematological Malignancies
AstraZeneca
EVICTION
ImCheck Therapeutics
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
BeOne Medicines
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
Biotroy Therapeutics
GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
Grit Biotechnology
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
Shanghai EpimAb Biotherapeutics Co., Ltd.
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
Janssen Research & Development, LLC
TWT-202
Treadwell Therapeutics, Inc
A Study of TAK-981 in People With Advanced Solid Tumors or Cancers in the Immune System
Takeda
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Sanofi
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation
Celgene
Compassionate Use Study of Tenalisib (RP6530)
Rhizen Pharmaceuticals SA
TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
Shenzhen TargetRx Co., Ltd.
Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL
CARsgen Therapeutics Co., Ltd.
Dose-range Finding Treosulfan-based Conditioning
medac GmbH
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Safety and Efficacy of SMART101 in Adult Patients With Hematological Malignancies After Haploidentical HSCT With Post-transplant Cyclophosphamide
Smart Immune SAS
ARIA
Ipsen
A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies
Bristol-Myers Squibb
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
Smart Immune SAS
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Fate Therapeutics
MT-3724NHL001
Molecular Templates, Inc.
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia
Glycostem Therapeutics BV
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
Genenta Science
A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Curon Biopharmaceutical (Australia) Co Pty Ltd
Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies
Gamida Cell ltd
FLORET
Menarini Group
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
Novartis
Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients
Novartis
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
Gamida Cell ltd
A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy
Mirror Biologics, Inc.
Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation
Cellect Biotechnology
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Regimmune Corporation